Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...
Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...
Rapporto annuale 2007 - Istituto di Ricerche Farmacologiche Mario ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
IRFMN<br />
Bianchi R., Gilar<strong>di</strong>ni A., Rodriguez-Menendez V., Oggioni V., Canta A., Colombo T., De<br />
Michele G., Martone S., Sfacteria A., Piedemonte G., Grasso G., Beccaglia P., Ghezzi P.,<br />
D’Incalci M., Lauria G., Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection<br />
by erythropoietin without affecting tumour growth. Eur J Cancer <strong>2007</strong>; 43: 710-717.<br />
Salvati E., Leonetti C., Rizzo A., Scarsella M., Mottolese M., Galati R., Sperduti I., Stevens<br />
M.F.G., D’Incalci M., Blasco M., Chiorino G., Bauwens S., Horard B., Gilson E., Stopacciaro<br />
A., Zupi G., Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an<br />
antitumor effect. J Clin Invest <strong>2007</strong>; 117: 3236-3247.<br />
Tavecchio M., Natoli C., Ubezio P., Erba E., D'Incalci M. Dynamics of cell cycle phase<br />
perturbations by trabecte<strong>di</strong>n (ET-743) in nucleotide excision repair (NER)-deficient and NERproficient<br />
cells, unravelled by a novel mathematical simulation approach. Cell Prolif <strong>2007</strong>; 40:<br />
885-904.<br />
Lupi M., Matera G., Natoli C., Colombo V., Ubezio P. The contribution of p53 in the dynamics<br />
of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle <strong>2007</strong>; 6:<br />
943-950.<br />
Sessa C., Cresta S., Cerny T., Baselga J., Rota Caremoli E., Malossi A., Hess D., Trigo J.,<br />
Zucchetti M., D'Incalci M., Zaniboni A., Capri G., Gatti B., Carminati P., Zanna C., Marsoni S.,<br />
Gianni L. Concerted escalation of dose and dosing duration in a phase I study of the oral<br />
camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol <strong>2007</strong>; 18:<br />
561-568.<br />
D'Incalci M., Steward W.P., Gescher A.J. Modulation of response to cancer chemotherapeutic<br />
agents by <strong>di</strong>et constituents. Is the available evidence sufficiently robust for rational advice for<br />
patients? Cancer Treat Rev <strong>2007</strong>; 33: 223-229.<br />
Bagnati R., Bianchi G., Marangon E., Zuccato E., Fanelli R., Davoli E. Direct analysis of<br />
isopropylthioxanthone (ITX) in milk by high-performance liquid chromatography/tandem mass<br />
spectrometry. Rapid Commun Mass Spectrom <strong>2007</strong>; 21: 1998-2002.<br />
Cavaletti G., Gilar<strong>di</strong>ni A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C.,<br />
Marmiroli P., Bossi M., Oggioni N., D'Incalci M., De Coster R. Bortezomib-induced peripheral<br />
neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol <strong>2007</strong>; 204:<br />
317-325.<br />
Gordon M.O., Torri V., Miglior S., Floriani I., Miller J.P., Gao F., Adamsons F., Poli D.,<br />
D'Agostino R.B., Kass M.A. Validated pre<strong>di</strong>ction model for the development for the<br />
development of primary open-angle glaucoma in in<strong>di</strong>viduals with ocular hypertension.<br />
Ophthalmology <strong>2007</strong>; 114: 10-19.<br />
Basse B., Ubezio P. A generalised age- and phase-structured model of human tumour cell<br />
populations both unperturbed and exposed to a range of cancer terapies. Bull Math Biol <strong>2007</strong>;<br />
69: 1673-1690.<br />
Vikhanskaya F., Lee M.K., Mazzoletti M., Broggini M., Sabapathy K. Cancer-derived p53<br />
mutants suppress p53-target gene expression-potential mechanism for gain of function of<br />
mutant p53. Nucleic Acids Res <strong>2007</strong>; 35: 2093-2104.<br />
28<br />
RAPPORTO ATTIVITA’ <strong>2007</strong>